



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	315992	Fe BioActive
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	1/04/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Fe BioActive

Product Type	Single Medicine Product	Effective Date	12/06/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support energy levels
Maintain/support energy production
Relieve weariness/tiredness/fatigue/feeling of weakness
Aid/assist healthy red blood cell production
Helps maintain/support transport of oxygen in the body
Helps maintain/support haemoglobin formation/synthesis
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
Maintain/support (state vitamin/mineral/nutrient) levels in the body
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Maintain/support nervous system health
Maintain/support nervous system function

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to chronic fatigue syndrome.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to heart disease.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING - When taken in excess of 3000 micrograms retinol equivalents, vitamin A can cause birth defects.

The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.

If you are pregnant, or considering becoming pregnant, do not take vitamin A supplements without consulting your doctor or pharmacist.

Not for the treatment of iron deficiency conditions (or words to that effect).

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Multiple containers	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Arthrospira platensis	100 mg
ascorbic acid	200 mg
betacarotene	2.7 mg
Equivalent: vitamin A	450 RE/microgram
Beta vulgaris root Extract dry concentrate	30 mg
Equivalent: Beta vulgaris (Dry)	240 mg
cupric citrate	545.4 microgram
Equivalent: copper	200 microgram
iron (II) glycinate	88.8 mg
Equivalent: iron	24 mg
levomefolate calcium	250 microgram
Equivalent: levomefolic acid	230.875 microgram
mecobalamin (co-methylcobalamin)	250 microgram
pyridoxal 5-phosphate monohydrate	24.59 mg
Equivalent: pyridoxine	15 mg

Other Ingredients (Excipients)

- calcium hydrogen phosphate dihydrate
- calcium hydrogen phosphate
- citric acid
- croscarmellose sodium
- dl-alpha-tocopherol
- glycerol
- hypromellose
- magnesium stearate
- maize starch
- maltodextrin



Australian Government

Department of Health
Therapeutic Goods Administration

microcrystalline cellulose
potable water
silicon dioxide
sodium ascorbate
starch sodium octenyl succinate
stearic acid
vegetable oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary